MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management
Open Access
- 1 January 2005
- journal article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2005 (1), 340-345
- https://doi.org/10.1182/asheducation-2005.1.340
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic, pre-malignant disorders characterized by monoclonal plasma cell proliferation in the bone marrow and absence of end-organ damage. Recent advances in the pathogenesis, natural history, and prognosis of MGUS and SMM are reviewed. A new risk stratification system to determine the prognosis of MGUS using the size and type of M protein, and the serum free light chain assay is discussed.Keywords
This publication has 26 references indexed in Scilit:
- Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined SignificanceJournal of Clinical Oncology, 2005
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005
- Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years LaterMayo Clinic Proceedings, 2004
- Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaLeukemia, 2004
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Prognostic value of angiogenesis in solitary bone plasmacytomaBlood, 2003
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Multiple myeloma: evolving genetic events and host interactionsNature Reviews Cancer, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- Smoldering Multiple MyelomaNew England Journal of Medicine, 1980